ALS Drug Development Gets FDA Hearing, Could See Push For Surrogate Markers
This article was originally published in The Pink Sheet Daily
Executive Summary
The ALS Association says it worked with FDA to seek a public forum in which ALS patients can present their perspective on benefit/risk in development of drugs for their condition.